Bionano GenomicsBNGOW 64 ROA % is -48.00% as of Mar. 2026. GuruFocus rates BNGOW with a GF Score™ of 64/100. The stock has 3 warning signs investors should review. Among 858 Medical Devices & Instruments companies, Bionano Genomics ranks worse than 82.98% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bionano Genomics's annualizedNet Income for the quarter that ended in Mar. 2026 was $-33.21 Mil.
Bionano Genomics's average Total Assets over the quarter that ended in Mar. 2026 was $69.19 Mil. Therefore, Bionano Genomics's annualized ROA % for the quarter that ended in Mar. 2026 was -48.00%.
The historical rank and industry rank for Bionano Genomics's ROA % or its related term are showing as below:
BNGOW'
s ROA % Range Over the Past 10 Years
Min: -187.42 Med: -89.89 Max: -33.11
Current: -42.48
During the past 10 years, Bionano Genomics's highest ROA % was -33.11%. The lowest was -187.42%. And the median was -89.89%.
BNGOW's ROA % is ranked worse than 82.98% of 858
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs BNGOW: -42.48
Bionano Genomics (NAS:BNGOW) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Bionano Genomics ROA % Related Terms
Bionano Genomics ROA % Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bionano Genomics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's ROA % distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Bionano Genomics (BNGOW) has a ROA % of -48.00% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bionano Genomics and its competitors. According to the industry distribution chart, Bionano Genomics ranks #712 out of 858 companies in the Medical Devices & Instruments industry, placing it in the top 83%.
Is Bionano Genomics' ROA % too high?
Bionano Genomics' current ROA % is -48.00%. Based on the distribution chart, Bionano Genomics ranks #712 out of 858 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' ROA % compare to UEEC and ZJYL?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #712 out of 858 companies for ROA %. This places Bionano Genomics in the lower half of its industry. The industry median ROA % is 0.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current ROA % is -48.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (BNGOW) has a current ROA % of -48.00%. The current ROA % is -48.00%. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current ROA % is -48.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
64GF Score
Get the complete analysis for BNGOW
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNGOW has been successfully added to your 
